HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid Tumors
Resolved · regulation · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-28. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
First patient dosing in Phase Ia triggers clinical development milestone progress for HUTCHMED and its partner GSK in targeted oncology.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factHUTCHMED initiated a Phase Ia global clinical trial for HMPL-A830 in patients with solid tumors. |
| What else was confirmed? | Reported factThe first patient was dosed on September 24, 2026. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for HCM yet — this is the next research task. |
| What would change the assessment? | UnknownPhase Ia Safety Cohort Data — Track initial safety and pharmacokinetic disclosures from Phase Ia trial enrollment. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · HUTCHMED initiated a Phase Ia global clinical trial for HMPL-A830 in patients with solid tumors.
- · The first patient was dosed on September 24, 2026.
- · HMPL-A830 is a first-in-class antibody conjugate combining a KRAS inhibitor with an anti-EGFR antibody, developed under an exclusive agreement with GSK.
Public research record
Research framework · page evidenceCompleted event assessment
clinical milestone progression in partnered oncology pipeline
| Type | Claim | Scope |
|---|---|---|
| Assumption | HUTCHMED initiated a Phase Ia global clinical trial for HMPL-A830 in patients with solid tumors. | 2026-09-28 |
| Interpretation | clinical milestone progression in partnered oncology pipeline | HCM |
Countercase, invalidators, and sources
Phase Ia dose-escalation demonstrates manageable toxicity and early biomarker signal across solid tumors.
- · Phase Ia Safety Cohort Data — Track initial safety and pharmacokinetic disclosures from Phase Ia trial enrollment.
- HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors · 2026-09-28
What remains unresolved
- Base path
- Dose escalation proceeds through planned cohorts over the next 12 months.
- Adverse path
- Dose-limiting toxicities emerge in early cohorts, requiring trial protocol amendments.
- Supportive path
- Phase Ia dose-escalation demonstrates manageable toxicity and early biomarker signal across solid tumors.
- · Phase Ia Safety Cohort Data — Track initial safety and pharmacokinetic disclosures from Phase Ia trial enrollment.next month
Evidence
- HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors2026-09-28
“HUTCHMED has initiated a Phase Ia global clinical trial of HMPL-A830, a first-in-class antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody for treating solid tumors. The first patient was dosed on September 24, 2026. HUTCHMED entered an exclusive development and...”
Supports: First patient dosed on September 24, 2026, in Phase Ia trial of HMPL-A830 partnered with GSK.